entertainment -WSS

entertainment

author：hotspot 2025-09-30 00:48:45 - browse：5

Two people run on the sugar-phosphate backbone of DNA while holding base pairs — in the lab coverage from STAT — Adobe

LONDON — Widespread genetic testing as well as the development of cutting-edge, customized genetic therapies have opened the door to treating many more inherited conditions than previously possible. A few recent cases, in which bespoke medicines were created for children with exceedingly rare mutations, have raised hopes for furthering the approach.

Now, researchers and government agencies in the U.K. are trying to figure out the nitty-gritty to replicate those early one-off successes for as many patients as possible — what sort of preclinical testing a tailor-made treatment needs to go through before being used, what regulatory thresholds each treatment needs to clear, and how to pay for these therapies.

“A lot of the barriers are no longer scientific — we can make these drugs,” said Matthew Wood, a professor of pediatrics at the University of Oxford. “It’s more about, can we make them at a cost that is reasonable enough? And can we get the regulators to reduce the barriers to doing this so that when a patient shows up, you can actually make a drug quickly enough to benefit that patient, rather than it costing huge amounts of money and taking two or three years to do it?”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Insurer loopholes limit power of law against surprise medical bills

WSS

Flint parents haunted by uncertainty, fears of lead poisoning

Late stage cancers on the rise after pandemic delayed screenings

Alnylam reports growth in sales of rare disease treatments

Who is Jack Smith, the special counsel overseeing the DOJ's Trump probes?

Readout Newsletter: Biogen, Eisai, Aardvark Therapeutics, etc.

Study: Black kids more likely to die after surgery than white kids

Wikipedia

entertainment

focus

Medicare details structure of new drug price negotiation program

Oral obesity drug from Viking Therapeutics hits key early target

Apple is now the first public company to be valued at $3 trillion

Alzheimer's risk factor APOE4 may be a distinct form of the disease

Tori Bowie and the unacceptable rates of Black maternal death

Insurer loopholes limit power of law against surprise medical bills

In Memoriam: Notable people who died in 2023

The a glaring gap in research on serious mental illness and primary care

23andMe had bad news about my health. I wish a person had delivered it

FDA scientists endorse Pfizer/BioNTech Covid

focus

Physicians aren't 'burning out.' They're suffering from moral injury

Four alarming medical procedures we’re glad history forgot

Study links childhood stress with decline in older age

First Opinion on colorectal cancer screening: letter and response

U.K. decision on ALS drug has neurologists, advocates up in arms

Four alarming medical procedures we’re glad history forgot

hotspot

explore

focus

leisure time